DYAI

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Wall Street analysts forecast DYAI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYAI is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dyadic International Inc revenue for the last quarter amounts to 1.16M USD, decreased -40.50 % YoY.

Dyadic International Inc. EPS for the last quarter amounts to -0.06 USD, increased 500.00 % YoY.

Dyadic International Inc (DYAI) has 6 emplpoyees as of December 15 2025.

Today DYAI has the market capitalization of 32.95M USD.